The Lancet Digital Health, December 2020, Volume 2, Issue 12, Pages e629-e680
Read the current issue of The Lancet Microbe, providing a destination for the best microbiology-focused clinical research
Related Articles
Social histories of public health misinformation and infodemics: case studies of four pandemics
Recognition of misinformation as a public health threat and interest in infodemics, defined as an inundation of information accompanying an epidemic or acute health event,…
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Treatment with GST-HG171 plus Ritonavir has demonstrated benefits in symptom recovery and viral clearance among low-risk vaccinated adult patients with COVID-19, without apparent safety concerns.…
The Lancet Rheumatology Home Page
Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide
Long COVID and SARS-CoV-2 persistence: new answers, more questions
In their study in The Lancet Infectious Diseases, Wenting Zuo and colleagues collected tissue samples from 225 patients who had recovered from mild COVID-19 and…
The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China
Our findings suggest that residual SARS-CoV-2 can persist in patients who have recovered from mild COVID-19 and that there is a significant association between viral…
GLP-1 analogue therapy for obesity in people from Asia
Obesity and overweight has become prevalent in Asian populations. It is estimated that 1 billion people across Asia have a BMI higher than 25 kg/m2,1…
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
The results of this study support the use of semaglutide 2·4 mg for weight management in people of east Asian ethnicity with overweight or obesity…
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However,…
An anti-PCSK9 pill a day to keep cholesterol away: next steps?
Elevated plasma LDL cholesterol is a major cause of atherosclerotic cardiovascular disease. Accordingly, all clinical practice guidelines advise decreasing LDL cholesterol to very low concentrations…
Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial
Intravenous tranexamic acid did not reduce haematoma growth when administered within 2 h of intracerebral haemorrhage symptom onset. There were no observed effects on other…
